GSK
GSK is a global healthcare company aiming to improve the health of 2.5 billion people by 2030, with a strong focus on R&D in infectious diseases, HIV, immunology/respiratory, and oncology.
Services
GSK provides a wide range of healthcare services, focusing primarily on pharmaceuticals, vaccines, and consumer healthcare. The company aims to positively impact the health of 2.5 billion people by the end of the decade. GSK delivers over 1.5 million doses of vaccines daily and offers specialty medicines for conditions such as HIV, respiratory diseases, cancer, and autoimmune diseases. Additionally, their general medicines portfolio includes treatments for asthma, COPD, antibiotics, and skin diseases. GSK's research and development endeavors are concentrated in several locations globally, ensuring a consistent pipeline of innovative healthcare solutions.
R&D and Innovation
GSK invests heavily in research and development, with a 2023 R&D budget of £6.2 billion. The company focuses on four main therapeutic areas: infectious diseases, HIV, immunology/respiratory, and oncology. GSK has a robust pipeline with 71 assets, including 18 in phase III/registration. The company operates four global R&D centers located in the US, UK, Belgium, and Italy. GSK leverages advanced technology platforms such as AI, machine learning, and functional genomics to drive innovation. Additionally, they develop and commercialize vaccines through various platform technologies, including mRNA.
Vaccine Portfolio
GSK has a robust portfolio of vaccines, with more than 20 marketed vaccines and 71 in development. Every day, the company delivers over 1.5 million doses globally. GSK's partnership with Gavi, the Vaccine Alliance, has been instrumental in providing vaccines for cervical cancer, pneumococcal disease, and rotavirus. They also have a long-standing commitment to supplying oral polio vaccines to UNICEF. GSK's vaccine price freeze commitment ensures affordability for countries transitioning out of Gavi support. This extensive vaccine portfolio highlights GSK's role as a leading vaccine supplier worldwide.
Global Presence
GSK maintains a significant global presence with R&D locations in Belgium, China, Germany, India, Italy, Japan, Poland, Singapore, Spain, Switzerland, the UK, and the US. The company's general medicines portfolio comprises over 150 primary care products available in 112 countries. Additionally, GSK's strategic partnerships and initiatives, such as the long-term collaboration with Gavi, demonstrate their commitment to making healthcare accessible worldwide. These global operations enable GSK to address diverse healthcare needs and bring innovative treatments to market efficiently.
Access to Medicine
GSK has been ranked 1st in the Access to Medicine Index for eight consecutive times, reflecting their commitment to making medications accessible to underserved populations. ViiV Healthcare, a subsidiary focused on HIV, is dedicated to widening access to HIV treatments globally. GSK's partnership with Gavi and its vaccine price freeze commitment for 10 years after countries transition out of Gavi support further demonstrate their efforts in improving global health. These initiatives highlight GSK's dedication to ensuring that essential medications and vaccines are available to those who need them most.